Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$76.56
+1.9%		$67.47
$23.65
▼
$77.00
$6.66B0.23904,422 shs810,778 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.29
+2.2%		$3.31
$2.77
▼
$7.18
$1.71B1.0319.15 million shs13.99 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$51.89
-1.9%		$50.15
$27.07
▼
$58.49
$6.44B0.691.09 million shs827,025 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$64.23
+1.4%		$60.45
$32.78
▼
$72.66
$6.12B0.62763,816 shs507,484 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+1.94%+10.72%+1.75%+6.23%+208.09%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+2.17%+3.46%-7.58%+4.44%-38.62%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-1.95%+13.17%-8.50%+5.49%+62.41%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+1.37%+3.16%-6.80%+16.78%+92.13%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$76.56
+1.9%		$67.47
$23.65
▼
$77.00
$6.66B0.23904,422 shs810,778 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.29
+2.2%		$3.31
$2.77
▼
$7.18
$1.71B1.0319.15 million shs13.99 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$51.89
-1.9%		$50.15
$27.07
▼
$58.49
$6.44B0.691.09 million shs827,025 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$64.23
+1.4%		$60.45
$32.78
▼
$72.66
$6.12B0.62763,816 shs507,484 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+1.94%+10.72%+1.75%+6.23%+208.09%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+2.17%+3.46%-7.58%+4.44%-38.62%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-1.95%+13.17%-8.50%+5.49%+62.41%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+1.37%+3.16%-6.80%+16.78%+92.13%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$83.188.65% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$8.10146.20% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.12
Buy$56.799.43% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$77.1320.09% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CGON, SRRK, and XENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$65.00
8/10/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$74.00
8/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$58.00
8/7/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$82.00 ➝ $81.00
8/7/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$76.00
8/7/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$58.00 ➝ $60.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $85.00
7/29/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$100.00
7/21/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$58.00
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,679.77N/AN/A$9.33 per share8.21
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M23.34N/AN/A$2.14 per share1.54
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$2.41 per shareN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M827.88N/AN/A$7.53 per share8.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-26.58%-25.34%N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$1.04N/AN/AN/A-945.94%-50.41%-38.25%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.45N/AN/AN/AN/A-159.92%-90.71%N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%N/A

Latest RXRX, CGON, SRRK, and XENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/6/2026Q2 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8405-$0.84+$0.0005-$0.84$3.33 millionN/A
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
8/5/2026Q2 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24-$0.25-$0.01-$0.25$10.97 million$7.67 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
31.30
31.25
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.01
5.03
5.03
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.71
8.64
8.64
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.64 million84.39 millionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400529.91 million494.67 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
140121.79 million109.24 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21096.67 million93.85 millionOptionable

Recent News About These Companies

Equities Analysts Set Expectations for XENE Q1 Earnings
August 10 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951472
Brokers Issue Forecasts for XENE Q1 Earnings
August 10 at 1:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brokers-issue-forecasts-for-xene-q1-earnings-2026-08-10/
Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE
August 9 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-purchases-30816-shares-of-xenon-pharmaceuticals-inc-xene-2026-08-09/
Xenon anticipates AZK NDA submission later this quarter, while funding operations into 2029
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4628882-xenon-anticipates-azk-nda-submission-later-this-quarter-while-funding-operations-into-2029
Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/xenon-pharmaceuticals-apos-azetukalner-nda-180212752.html
Xenon Pharmaceuticals Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-q2-earnings-call-highlights-2026-08-07/
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971054/xene-s-q2-loss-narrower-than-expected-sales-nil-pipeline-in-focus?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2971054
California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-36183-shares-of-xenon-pharmaceuticals-inc-xene-2026-08-07/
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932743-xenon-pharmaceuticals-inc-xene-q2-2026-earnings-call-transcript
Xenon Pharmaceuticals Q2 Loss Widens
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/xenon-pharmaceuticals-q2-loss-widens-213531400.html
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-nasdaqxene-announces-quarterly-earnings-results-2026-08-06/
Xenon Reports Q2 2026 Financial Results and Provides Business Update
August 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/xenon-reports-q2-2026-financial-results-and-provides-business-update-1036422683
Xenon Pharma Q2 2026 earnings preview
August 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/xenon-pharma-q2-2026-earnings-preview/ar-AA29u2E5
Xenon Pharmaceuticals Inc. $XENE Shares Bought by Sei Investments Co.
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-xenon-pharmaceuticals-inc-xene-shares-bought-by-sei-investments-co-2026-08-04/
Xenon Pharmaceuticals (XENE) to Release Earnings on Thursday
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-xene-to-release-earnings-on-thursday-2026-08-02/
Lazard Asset Management LLC Sells 27,908 Shares of Xenon Pharmaceuticals Inc. $XENE
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-lazard-asset-management-llc-sells-27908-shares-of-xenon-pharmaceuticals-inc-xene-2026-08-02/
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Increased to Sell at Wall Street Zen
August 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30933229
Xenon Pharmaceuticals (NASDAQ:XENE) Raised to Sell at Wall Street Zen
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-nasdaqxene-raised-to-sell-at-wall-street-zen-2026-08-01/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2026  |  financialpost.comF
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3337042/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Janus Henderson Group PLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-janus-henderson-group-plc-boosts-stock-position-in-xenon-pharmaceuticals-inc-xene-2026-07-31/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$76.56 +1.46 (+1.94%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$76.75 +0.19 (+0.25%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$3.29 +0.07 (+2.17%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$3.31 +0.02 (+0.67%)
As of 07:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$51.89 -1.03 (-1.95%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$52.31 +0.42 (+0.82%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$64.23 +0.87 (+1.37%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$64.44 +0.21 (+0.33%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas